ProCE Banner Activity

JACKPOT8 Part B: Pivotal Phase II Study of Golidocitinib, a JAK1-Selective Inhibitor, in Relapsed/Refractory PTCL

Conference Coverage
Slideset

Pivotal phase II results from JACKPOT8 part B demonstrate durable response rate and safety of JAK1-selective inhibitor golidocitinib monotherapy in patients with relapsed/refractory PTCL.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis